AFA urges FDA to wait for McNeil raw data on aspirin/alcohol link at "feedback" meeting.
• By The Tan Sheet
AFA URGES FDA TO WAIT FOR McNEIL RAW DATA ON ASPIRIN/ALCOHOL INTERACTION before proposing an alcohol warning on aspirin products. At a July 11 "OTC feedback" meeting, Aspirin Foundation of America outside counsel Bruce Dickson (Washington, D.C. law firm Paul, Hastings, Janofsky & Walker) objected to FDA's plan to require an alcohol warnings on aspirin-containing OTC analgesics ("The Tan Sheet" Jan. 16, p. 3).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.